Altre lingue ExpreS2ion Biotech Holding AB

Azioni

EXPRS2

SE0008348262

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 17:29:30 03/05/2024			Variaz. 5gg	Var. 1 gen.
1,454 ^SEK	-45,34%		-46,93%	-31,09%

16/04	ExpreS2ion annuncia il completamento dello studio di sicurezza GLP per il candidato vaccino contro il cancro al seno ES2B-C001 (HER2-VLP)	CI
21/02	La JV ExpreS2ion Biotech ottiene 10 milioni di euro in seguito al completamento da parte di Bavarian Nordic dello studio sul vaccino COVID-19	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)	03/05
ExpreS2ion announces a rights issue of units of approximately SEK 60 million	02/05
ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS	23/04
ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023	16/04
ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate	16/04
ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	16/04
ExpreS2ion to present in investor and R&D events in March	15/04
ExpreS2ion to present in investor and R&D events in March	29/02
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	21/02
ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine	21/02
ExpreS2ion announces financial results for the fourth quarter and full-year 2023	08/02
ExpreS2ion to present in Redeye Fight Cancer event and the Bio Innovation Leaders Summit	22/01
ExpreS2ion to present new Nipah virus vaccine project in upcoming webcast	12/12
Pareto Securities publishes research report	04/12
ExpreS2ion Biotech Unit Secures EUR8 Million Grant for Virus Vaccine Project; Shares Soar	01/12
ExpreS2ion announces new EU-funded Horizon Europe grant award for Nipah virus vaccine development	01/12
ExpreS2ion CEO interviewed, CFO provides update at life science investor conference, Analysguiden publishes research report	27/11
ExpreS2ion announces financial results for the third quarter 2023	16/11
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11
ExpreS2ion Biotechnologies: Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB held on 9 November 2023	09/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue ExpreS2ion Biotech Holding AB

Azioni

EXPRS2

SE0008348262

Altre lingue

Filtri